Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK's C. difficile F2 Vaccine
NCT04026009Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACAM-CDIFF in Clostridium difficile infection (CDI) (5 arms), sponsored by GSK. Primary endpoints: Number of Subjects With Any and Grade 3 Solicited Local Symptoms, Number of Subjects With Any, Grade 3, Related and Grade 3 Related Solicited General Symptoms and 4 more. Started Aug 2019; status: completed.
02
Drugs
ACAM-CDIFF
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT04026009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04026009.